CANbridge Pharmaceuticals Inc. (1228) Releases Supplemental Details on Share Options and RSUs

Bulletin Express

Yesterday

CANbridge Pharmaceuticals Inc. (the Group) issued a supplemental announcement regarding the grant of Share Options and Restricted Share Units (RSUs) originally disclosed in the announcement dated January 12, 2026. The update clarifies details about two external service providers who support the Group’s research and development strategy and regulatory approval processes.

The two service providers, identified as Service Provider 1 and Service Provider 2, offer long-term development strategy advice and regulatory consulting support, respectively. According to the Board, granting Share Options and RSUs aligns with the purpose of the schemes by reflecting the continuing and recurring nature of these services, as well as their importance to the Group’s business, growth, and development. No further supplementary information was provided beyond these clarifications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159185167"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159185167\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159185167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159185167","market":"hk","top_or_hot":-1,"title":"CANbridge Pharmaceuticals Inc. (1228) Releases Supplemental Details on Share Options and RSUs","media":"Bulletin Express","content":"<p>CANbridge Pharmaceuticals Inc. (the Group) issued a supplemental announcement regarding the grant of Share Options and Restricted Share Units (RSUs) originally disclosed in the announcement dated January 12, 2026. The update clarifies details about two external service providers who support the Group’s research and development strategy and regulatory approval processes.</p>\n<p>The two service providers, identified as Service Provider 1 and Service Provider 2, offer long-term development strategy advice and regulatory consulting support, respectively. According to the Board, granting Share Options and RSUs aligns with the purpose of the schemes by reflecting the continuing and recurring nature of these services, as well as their importance to the Group’s business, growth, and development. No further supplementary information was provided beyond these clarifications.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANbridge Pharmaceuticals Inc. (1228) Releases Supplemental Details on Share Options and RSUs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANbridge Pharmaceuticals Inc. (1228) Releases Supplemental Details on Share Options and RSUs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-20 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANbridge Pharmaceuticals Inc. (the Group) issued a supplemental announcement regarding the grant of Share Options and Restricted Share Units (RSUs) originally disclosed in the announcement dated January 12, 2026. The update clarifies details about two external service providers who support the Group’s research and development strategy and regulatory approval processes.</p>\n<p>The two service providers, identified as Service Provider 1 and Service Provider 2, offer long-term development strategy advice and regulatory consulting support, respectively. According to the Board, granting Share Options and RSUs aligns with the purpose of the schemes by reflecting the continuing and recurring nature of these services, as well as their importance to the Group’s business, growth, and development. No further supplementary information was provided beyond these clarifications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01228","symbol_name":"北海康成-B","start_time":0,"source_url":"","article_id":"1159185167","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159185167","pubTimestamp":1771576918,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CANbridge Pharmaceuticals Inc. (the Group) issued a supplemental announcement regarding the grant of Share Options and Restricted Share Units (RSUs) originally disclosed in the announcement dated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01228":"北海康成-B"},"translate_title":"CANbridge Pharmaceuticals Inc.(1228)发布有关股票期权和受限制股份单位的补充详细信息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":1},"content_text":"CANbridge Pharmaceuticals Inc. (the Group) issued a supplemental announcement regarding the grant of Share Options and Restricted Share Units (RSUs) originally disclosed in the announcement dated January 12, 2026. The update clarifies details about two external service providers who support the Group’s research and development strategy and regulatory approval processes.\nThe two service providers, identified as Service Provider 1 and Service Provider 2, offer long-term development strategy advice and regulatory consulting support, respectively. According to the Board, granting Share Options and RSUs aligns with the purpose of the schemes by reflecting the continuing and recurring nature of these services, as well as their importance to the Group’s business, growth, and development. No further supplementary information was provided beyond these clarifications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}